Among the awarded researchers is Itziar Salaverria, head of the Molecular Genetics of Pediatric Lymphomas research group at IDIBAPS, who has received recognition from the CRIS Emerging Leader Program. This call encourages researchers who are consolidating their scientific careers and leading innovative projects in oncology.
The award will finance a 5-year project focused on pediatric non-Hodgkin lymphoma, one of the most common neoplasms in children and adolescents, with 400,000 euros. Despite good response rates to current treatments, a significant proportion of patients suffer from serious long-term side effects, and the prognosis for cases that relapse remains very unfavorable. The objective of the project is to characterize in depth this type of lymphoma in children from a genetic, molecular, immunological and clinical point of view, to improve the prediction of the risk of relapse and move towards more personalized and less toxic treatments.
The initiative will be developed within the framework of a broad national and international collaboration, with the participation of the non-Hodgkin lymphoma group of the Spanish Society of Pediatric Hematology and Oncology and several European reference centers.
This research is conducted within the framework of the Clínic Barcelona Comprehensive Cancer Centre (4CB), promoted by Hospital Clínic, IDIBAPS and the University of Barcelona.
